Dedifferentiated Fat Cells Combined with Acellular Dermal Matrix to Promote the Survival of Grafted Fat: Basic Research.
Dong M., Ma X., Li F.
Animal Study, published in Plast Reconstr Surg (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Plast Reconstr Surg (2025)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40561444
- DOI
- 10.1097/PRS.0000000000011989
Abstract (original English)
Dedifferentiated fat cells (DFATs) are derived from mature adipocytes that undergo dedifferentiation and regain proliferative and differentiation potential. Acellular dermal matrix (ADM) is widely used in plastic and reconstructive medicine. The effects of ADM combined with DFATs in fat transplantation have not been studied. The microstructure of ADM was tested in vitro. Adipogenic gene and angiogenic factors secreted by adipose-derived stem cells or DFATs seeded on ADM were measured. In vivo experiments involved preculturing DFATs on ADM and then mixing them with adipose tissue for transplantation into nude mice (1:2). Samples were collected at 4, 8, and 12 weeks for histologic analysis, quantitative reverse transcription polymerase chain reaction, enzyme-linked immunosorbent assay, and immunostaining. ADM demonstrated good biocompatibility, and quantitative reverse transcription polymerase chain reaction showed that in vitro preculture enhanced the expression of adipogenic-related genes (PPARγ and CEBPα) in DFATs and increased the secretion of vascular endothelial growth factor (P < 0.05). In the animal experiments, the fat grafts mixed with ADM exhibited better fat integrity and lower fibrosis levels, and enzyme-linked immunosorbent assay showed that interleukin-1β and tumor necrosis factor α levels were decreased. In the DFATs + ADM group, the numbers of CD31-positive cells
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.